Invivyd, Inc. (NASDAQ:IVVD) Sees Significant Increase in Short Interest

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,980,000 shares, an increase of 8.4% from the December 31st total of 3,670,000 shares. Based on an average trading volume of 958,500 shares, the short-interest ratio is presently 4.2 days. Approximately 5.3% of the shares of the company are sold short.

Insider Transactions at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 119,805 shares of Invivyd stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $0.42, for a total value of $50,318.10. Following the transaction, the director now directly owns 3,568,274 shares in the company, valued at approximately $1,498,675.08. This trade represents a 3.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 816,466 shares of company stock worth $423,214. Insiders own 17.90% of the company's stock.

Institutional Trading of Invivyd

Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC purchased a new stake in shares of Invivyd in the 2nd quarter worth about $421,000. Marshall Wace LLP grew its position in shares of Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company's stock valued at $866,000 after purchasing an additional 31,992 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Invivyd by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company's stock worth $148,000 after purchasing an additional 53,499 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Invivyd during the 2nd quarter worth approximately $115,000. Finally, Proficio Capital Partners LLC purchased a new stake in Invivyd in the 3rd quarter valued at approximately $27,000. Institutional investors and hedge funds own 70.36% of the company's stock.

Invivyd Trading Up 3.0 %

Shares of NASDAQ:IVVD traded up $0.06 during trading on Friday, hitting $2.04. 27,285,427 shares of the stock were exchanged, compared to its average volume of 30,464,357. Invivyd has a 12-month low of $0.35 and a 12-month high of $5.10. The company has a market cap of $244.02 million, a PE ratio of -1.04 and a beta of 0.61. The company has a fifty day moving average price of $0.58 and a two-hundred day moving average price of $0.84.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on IVVD shares. Morgan Stanley dropped their price objective on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating on the stock in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a "strong-buy" rating in a research report on Wednesday, October 30th. D. Boral Capital reissued a "buy" rating and issued a $9.00 price target on shares of Invivyd in a report on Monday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Invivyd in a report on Tuesday. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Invivyd currently has a consensus rating of "Buy" and an average price target of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.